Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis-Reference-Cited by-同舟云学术

Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis

Published:2018-05-02 Issue:1 Volume:18 Page:
ISSN:1471-2261
Container-title:BMC Cardiovascular Disorders
language:en
Short-container-title:BMC Cardiovasc Disord

Author:

Bundhun Pravesh Kumar,Huang Feng^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12872-018-0820-6.pdf

Reference31 articles.

1. Rodriguez AE, Rodriguez-Granillo AM, Ascarrunz SD, Peralta-Bazan F, Cho MY. Did Prasugrel and Ticagrelor offer the same benefit in patients with acute coronary syndromes after percutaneous coronary interventions compared to Clopidogrel? Insights from randomized clinical trials, registries and meta-analysis. Curr Pharm Des. 2018; https://doi.org/10.2174/1381612824666180108121834 .

2. Cherepanov V, Fortmann SD, Kim MH, Marciniak TA, Litvinov O, Mihalev K, Serebruany VL. Annual adverse event profiles after clopidogrel, prasugrel, and ticagrelor in the Food and Drug Administration adverse event reporting system. Eur Heart J Cardiovasc Pharmacother. 2017; https://doi.org/10.1093/ehjcvp/pvx038 .

3. Tarantini G, Ueshima D, D'Amico G, Masiero G, Musumeci G, Stone GW, Brener SJ. Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: a systematic review and meta-analysis. Am Heart J. 2018;195:78–85.

4. Aradi D, Komócsi A, Vorobcsuk A, Serebruany VL. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Thromb Haemost. 2013;109(1):93–101.

5. Bavishi C, Panwar S, Messerli FH, Bangalore S. Meta-analysis of comparison of the newer oral P2Y12 inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in patients with non-ST-elevation acute coronary syndrome. Am J Cardiol. 2015;116(5):809–17.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Associations between hemoglobin A1c levels and platelet reactivity and their impact on outcomes in patients after coronary insertion of drug-eluting stents;2024-08-28

2. Prevalence of Periprocedural Complications and Associated Factors of Percutaneous Coronary Intervention in Patients with Ischemic Heart Disease at Coronary Care Units of Tikur Anbessa Specialized Hospital and Gesund Cardiac and Medical Center, Addis Ababa, Ethiopia: A Retrospective Cohort Study;Research Reports in Clinical Cardiology;2023-09

3. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies;Health Technology Assessment;2023-05

4. De-Escalation Dual Antiplatelet Therapy Prevail over Potent P2Y12 Inhibitor Monotherapy in Patients with Acute Coronary Syndrome Undergone Percutaneous Coronary Intervention: A Network Meta-Analysis;Reviews in Cardiovascular Medicine;2022-10-25

5. Oral Antiplatelet Agents in Percutaneous Coronary Intervention;Interventional Cardiology;2022-05-06